

Maurie Markman

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/325832/maurie-markman-publications-by-year.pdf>

Version: 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

311
papers

6,360
citations

34
h-index

78
g-index

390
ext. papers

7,000
ext. citations

4
avg, IF

6.05
L-index

#	Paper	IF	Citations
311	HPV vaccination as a strategy for cancer prevention. <i>Future Virology</i> , 2020 , 15, 67-70	2.4	1
310	Differences in presentation and survival of Asians compared to Caucasians with ovarian cancer: An NRG Oncology/GOG Ancillary study of 7914 patients. <i>Gynecologic Oncology</i> , 2019 , 154, 420-425	4.9	7
309	The Evolving Arena of Ovarian Cancer Maintenance Therapy. <i>Oncology</i> , 2019 , 97, 202-205	3.6	2
308	Pharmaceutical Management of Ovarian Cancer: Current Status. <i>Drugs</i> , 2019 , 79, 1231-1239	12.1	19
307	Poly (ADP-ribose) polymerase inhibitors in the management of ovarian cancer. <i>Women's Health</i> , 2018 , 14, 1745505717750694	3	6
306	The Requirement for Increasingly Effective Societal Cancer Control Efforts. <i>Current Oncology Reports</i> , 2018 , 20, 9	6.3	1
305	Response to rapamycin analogs but not PD-1 inhibitors in PTEN-mutated metastatic non-small-cell lung cancer with high tumor mutational burden. <i>Lung Cancer: Targets and Therapy</i> , 2018 , 9, 45-47	2.9	9
304	Cardio-Oncology: mechanisms of cardiovascular toxicity. <i>F1000Research</i> , 2018 , 7, 113	3.6	7
303	Self-forgiveness is associated with reduced psychological distress in cancer patients and unmatched caregivers: Hope and self-blame as mediating mechanisms. <i>Journal of Psychosocial Oncology</i> , 2017 , 35, 544-560	2.8	8
302	Case of Ovarian Cancer in a Woman with Undiagnosed Graves Disease: A Case Report and Review of the Literature. <i>Case Reports in Oncology</i> , 2017 , 10, 452-454	1	
301	Treatment of Leptomeningeal Metastases in a Patient with Non-Small Cell Lung Cancer Harboring EGFR T790M Mutation. <i>Case Reports in Oncology</i> , 2017 , 10, 840-845	1	4
300	Optimism and the continued promise of maintenance chemotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2017 , 80, 879-880	3.5	1
299	A Case Report Demonstrating the Potential Clinical Relevance of Liquid Tumor Biopsies in Lung Cancer. <i>Case Reports in Oncology</i> , 2016 , 9, 714-717	1	0
298	Rational study endpoints in anti-neoplastic agent regulatory approval trials in the gynecologic malignancies. <i>Women's Health</i> , 2016 , 12, 396-9	3	
297	Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer: Where Do We Go From Here?. <i>Oncologist</i> , 2016 , 21, 529-31	5.7	3
296	Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1460-6	2.2	196
295	Targeted Therapy in Solid Tumors: Lung Cancer 2015 , 224-230		

294 Toward Personalized Therapy for Cancer **2015**, 3-13

293 Targeted and Functional Imaging **2015**, 101-110

292 Targeted Therapies in Chronic Myeloid Leukemia **2015**, 111-120

291 Targeted Therapy for Acute Lymphoblastic Leukemia **2015**, 121-129

290 Chronic Lymphocytic Leukemia **2015**, 130-144

1

289 The Impact of Genomics on Targeted Therapy in Multiple Myeloma and Lymphomas **2015**, 157-161

288 Targeted Therapy in Myelodysplastic Syndromes **2015**, 162-168

287 Lymphoma and Targeted Therapies **2015**, 169-176

286 Targeted Therapy in Solid Tumors: Brain **2015**, 177-189

285 Targeted Therapy for Breast Cancer **2015**, 190-192

284 Combining Targeted Therapies **2015**, 14-26

283 Targeted Therapy in Solid Tumors: Colorectal Cancer **2015**, 193-204

282 Targeted Therapy in Solid Tumors: Head and Neck **2015**, 216-223

281 Targeted Therapy in Melanoma **2015**, 231-239

280 Molecular Therapeutics: Pancreatic Cancer **2015**, 255-262

279 Targeted Therapies for Pediatric Solid Tumors **2015**, 263-272

278 Renal Cell Carcinoma and Targeted Therapy **2015**, 287-295

1

277 Principles of Targeted Immunotherapy **2015**, 27-38

276	Targeted Therapy in Solid Tumors: Sarcomas 2015 , 296-301		
275	RAS-RAF-MEK Pathway: Aberrations and Therapeutic Possibilities 2015 , 303-314		
274	The Phosphatidylinositol 3-Kinase Pathway in Human Malignancies 2015 , 315-324		
273	Current Status and Future Direction of PARP Inhibition in Cancer Therapy 2015 , 325-340		
272	Targeting the c-Met Kinase 2015 , 341-346		
271	KIT Kinase 2015 , 347-352		
270	TP53 2015 , 353-359		
269	Cancer Stem Cell Principles 2015 , 39-46		1
268	The Tumor Microenvironment as a Target for Therapeutic Intervention 2015 , 47-63		
267	The Role of Angiogenesis in Cancer 2015 , 64-71		4
266	Epigenetics and Epigenetic Therapy of Cancer 2015 , 72-79		
265	The Role of microRNAs in Cancer 2015 , 80-88		2
264	Acute Myeloid Leukemia 2015 , 89-100		1
263	Signet-Ring Cell Carcinoma of the Colon: A Case Report and Review of the Literature. <i>Case Reports in Oncology</i> , 2015 , 8, 466-71	1	12
262	Metastatic Breast Cancer with Extensive Osseous Metastasis Presenting with Symptomatic Immune Thrombocytopenic Purpura and Anemia: A Case Report and Review of the Literature. <i>Case Reports in Oncology</i> , 2015 , 8, 256-63	1	1
261	Maintenance chemotherapy in the management of epithelial ovarian cancer. <i>Cancer and Metastasis Reviews</i> , 2015 , 34, 11-7	9.6	18
260	Pegylated liposomal Doxorubicin-induced acute transient encephalopathy in a patient with breast cancer: a case report. <i>Case Reports in Oncology</i> , 2014 , 7, 228-32	1	3
259	Acquired Aplastic Anemia 2014 , 131-134		

258 Primary CNS Lymphoma **2014**, 308-315

257 Hematopoietic Cell Transplantation in Chronic Myeloid Leukemia **2014**, 180-186

256 Management of Acute Promyelocytic Leukemia **2014**, 71-75

255 Diffuse Large B-Cell Lymphoma **2014**, 263-269

254 Dangers of "confirmatory" cancer trials that fail to actually test the original hypothesis. *Current Oncology Reports*, **2014**, 16, 381 6.3

253 Cardiotoxicity of antineoplastic agents: what is the present and future role for imaging?. *Current Oncology Reports*, **2014**, 16, 396 6.3 10

252 Cyclophosphamide-induced severe acute hyponatremic encephalopathy in patients with breast cancer: report of two cases. *Case Reports in Oncology*, **2014**, 7, 550-4 1 7

251 An experience with managing cancer patients reportedly previously informed of the absence of additional available antineoplastic therapeutic options. *Case Reports in Oncology*, **2014**, 7, 633-7 1

250 Naturopathic Medicine in Oncology **2014**, 879-883

249 Cancer Survivorship and Psychosocial Issues in Oncology **2014**, 896-901

248 Musculoskeletal Care in Oncology **2014**, 893-895

247 Anesthesiology Consultation for Localized Cancer Pain **2014**, 884-892

246 Pitfalls in the Diagnosis of Myelodysplastic Syndromes **2014**, 97-105

245 Hematopoietic Cell Transplantation in Adult Acute Lymphoblastic Leukemia **2014**, 40-47

244 Minimal Residual Disease in Acute Lymphoblastic Leukemia **2014**, 35-39

243 Management of T-Cell Acute Lymphoblastic Leukemia **2014**, 29-34

242 Management of B-Cell Acute Lymphoblastic Leukemia **2014**, 22-28

241 Prognostic Markers and Models in Acute Lymphoblastic Leukemia **2014**, 18-21

- 240 Consolidation Therapy in Acute Myeloid Leukemia **2014**, 67-70
- 239 Induction Therapy in Acute Myeloid Leukemia **2014**, 58-66 1
- 238 Prognosis in Acute Myeloid Leukemia: Cytogenetics and Beyond **2014**, 49-57
- 237 Management of Therapy-Related Myeloid Neoplasms **2014**, 120-125
- 236 Management of Myelodysplastic Syndromes **2014**, 113-119
- 235 Cytogenetics and Prognostic Models in Myelodysplastic Syndromes **2014**, 106-112
- 234 Relapsed and Refractory Acute Myeloid Leukemia **2014**, 82-88
- 233 Minimal Residual Disease in Acute Myeloid Leukemia **2014**, 76-81
- 232 Challenging the requirements for disclosing risk to clinical research participants. *American Journal of Bioethics*, **2014**, 14, 11-2 1.1 1
- 231 Mycosis Fungoides and Sézary Syndrome **2014**, 323-326
- 230 Diagnosis of Acute Lymphoblastic Leukemia **2014**, 1-17
- 229 Hematopoietic Cell Transplantation in Myelodysplastic Syndromes **2014**, 126-130
- 228 Advances in cervical cancer pharmacotherapies. *Expert Review of Clinical Pharmacology*, **2014**, 7, 219-23 3.8 15
- 227 Hematopoietic Cell Transplantation in Acute Myeloid Leukemia **2014**, 89-95
- 226 Germ Cell Tumors **2014**, 645-650
- 225 Soft Tissue Sarcomas **2014**, 696-703
- 224 Hairy Cell Leukemia **2014**, 220-225
- 223 Primary Mediastinal Large B-Cell Lymphoma **2014**, 282-285

222 Methodological and Practical Challenges for Personalized Therapies in Non-Small-Cell Lung Cancer **2014**, 480-485

221 Hematopoietic Cell Transplantation in Hodgkin Lymphoma **2014**, 240-244

220 Medical Management of Melanoma **2014**, 651-660

219 Nonmelanoma Skin Cancers **2014**, 661-666

218 Ovarian Cancer: Neoadjuvant, Adjuvant, and Surgical Issues **2014**, 667-674

217 Bone Sarcomas **2014**, 687-695

216 Surgical Aspects of Head and Neck Cancers **2014**, 705-710

215 Surgical Aspects of Thoracic Malignancies **2014**, 711-718

214 Surgical Aspects of Upper Gastrointestinal Cancers **2014**, 719-722

213 Surgical Aspects of Pancreatic Cancer **2014**, 723-728

212 Surgical Aspects of Hepatobiliary Tumors **2014**, 729-734

211 Surgical Aspects of Lower Gastrointestinal Cancers **2014**, 735-738

210 Surgical Aspects of Renal Cancer **2014**, 739-743

209 Surgical Aspects of Bladder Cancer **2014**, 744-746

208 Surgical Aspects of Prostate Cancer **2014**, 747-753

207 Surgical Aspects of Melanoma **2014**, 754-758

206 Radiotherapy for Head and Neck Cancers **2014**, 759-766

1

205 Radiotherapy for Ductal Carcinoma in Situ (DCIS) **2014**, 767-770

- 204 Radiotherapy for Early-Stage Invasive Breast Cancer **2014**, 771-777
- 203 Radiotherapy for Thoracic Malignancies **2014**, 778-784
- 202 Radiotherapy for Gastrointestinal Malignancies **2014**, 785-788
- 201 Radiotherapy for Genitourinary Malignancies **2014**, 789-792
- 200 When to Suspect Hereditary Cancer Syndromes **2014**, 793-799
- 199 Hereditary Breast Cancer Syndromes **2014**, 800-803
- 198 Genetic Testing in Gastrointestinal Tumors **2014**, 804-809
- 197 Hereditary Urogenital Cancer Syndromes **2014**, 810-814
- 196 Carcinoma of Unknown Primary (CUP) **2014**, 815-821
- 195 Geriatric Oncology **2014**, 822-825
- 194 Nuts and Bolts of Cancer Immunotherapy **2014**, 826-830
- 193 Controversies Related to Oncology Clinical Trial Development **2014**, 831-834
- 192 PET Scan in Oncology **2014**, 835-840
- 191 Hematopoietic Growth Factors **2014**, 841-843
- 190 Anticoagulation Issues in Oncology **2014**, 844-850
- 189 Symptom Management and Palliative Care **2014**, 851-859
- 188 Metabolic and Nutritional Issues in Oncology **2014**, 860-866
- 187 Bone-Related Issues in Oncology **2014**, 867-871

186 Integrative Medicine in Oncology **2014**, 872-878

185 Diagnostic Approach in Myeloproliferative Neoplasms **2014**, 135-141

184 Chronic Myeloid Leukemia: Chronic Phase **2014**, 142-146

183 Blast Crisis of Chronic Myeloid Leukemia **2014**, 147-149

182 Chronic Myeloid Leukemia and Pregnancy **2014**, 150-151

181 Polycythemia Vera **2014**, 152-155

180 Essential Thrombocytosis **2014**, 156-161

179 Primary Myelofibrosis **2014**, 162-166

178 Eosinophilic Myeloproliferative Disorders **2014**, 167-175

177 Chronic Myelomonocytic Leukemia **2014**, 176-179

176 Hematopoietic Cell Transplantation in Primary Myelofibrosis **2014**, 187-191

175 Prognostic Markers and Management of Chronic Lymphocytic Leukemia **2014**, 193-200

174 Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia **2014**, 201-206

173 Prolymphocytic Leukemia **2014**, 207-219

172 Management of Classical Hodgkin Lymphoma **2014**, 227-234

171 Nodular Lymphocyte-Predominant Hodgkin Lymphoma **2014**, 235-239

170 Pitfalls in the Diagnosis of Non-Hodgkin Lymphomas **2014**, 245-256

169 Follicular Lymphoma **2014**, 257-262

168 Mantle Cell Lymphoma **2014**, 270-274

167 Marginal Zone Lymphoma **2014**, 275-281

166 Burkitt Lymphoma **2014**, 286-289

165 Gray Zone Lymphoma **2014**, 290-294

164 Transformed Lymphoma **2014**, 295-303

163 HIV-Associated Lymphoma **2014**, 304-307

162 Primary Cutaneous Lymphoma **2014**, 316-322

161 Hematopoietic Cell Transplantation in Indolent Non-Hodgkin's Lymphoma **2014**, 327-331

160 Hematopoietic Cell Transplantation in Diffuse Large B-cell Lymphoma **2014**, 332-338

159 Hematopoietic Cell Transplantation in T-Cell Non-Hodgkin's Lymphomas **2014**, 339-344

158 Smoldering Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance **2014**, 345-351

157 Risk Stratification and Response Assessment in Multiple Myeloma and Waldenström's Macroglobulinemia **2014**, 352-357

156 Treatment of Multiple Myeloma **2014**, 358-365

155 Light-Chain Amyloidosis **2014**, 366-370

154 Waldenström's Macroglobulinemia **2014**, 371-375

153 Autologous Hematopoietic Cell Transplantation in Multiple Myeloma **2014**, 376-380

152 Allogeneic hematopoietic cell transplantation in multiple myeloma **2014**, 381-387

151 Role of PET Scan in Lymphomas **2014**, 389-397

150 Radioimmunotherapy in Lymphomas **2014**, 398-402

149 Radiation Oncology Consultation for Hematologic Malignancies **2014**, 403-408

148 Donor and Graft Selection in Allogeneic Hematopoietic Cell Transplantation **2014**, 409-416

147 Preparative Regimens in Allogeneic Hematopoietic Cell Transplantation for Malignant Hematological Diseases **2014**, 417-420

146 T-Cell Depletion in Allogeneic Hematopoietic Cell Transplantation **2014**, 421-425

145 Prevention and Treatment of Relapse Following Hematopoietic Cell Transplantation **2014**, 426-431

144 Acute Graft-Versus-Host Disease **2014**, 432-437

143 Chronic Graft-Versus-Host Disease **2014**, 438-443

142 Primary Brain Tumors **2014**, 445-456

141 Secondary brain and spinal cord tumors **2014**, 457-464

140 Medical management of head and neck cancers **2014**, 465-475

139 Endocrine Malignancies **2014**, 476-479

138 Screening, Staging, and Stage I Non-Small-Cell Lung Cancer **2014**, 486-492

137 Stage II and III Non-Small-Cell Lung Cancer **2014**, 493-499

136 Recurrent and Metastatic Non-Small-Cell Lung Cancer and Novel Targets **2014**, 500-502

135 Small-Cell Lung Cancer **2014**, 503-505

134 Mesothelioma **2014**, 506-511

133 Immunohistochemistry Testing and Beyond in Breast Cancer **2014**, 513-522

132 Prevention and Adjuvant Therapy in Breast Cancer **2014**, 523-531

131 Preoperative Systemic Therapy for Breast Cancer **2014**, 532-539

130 Recurrent and Metastatic Breast Cancer **2014**, 540-545

129 Special Issues in the Young and Pregnant Patient with Breast Cancer **2014**, 546-552

128 Early-Stage Esophageal and Stomach Cancers **2014**, 553-561

127 Metastatic Esophagogastric Cancer: Controversies, Consensus, and New Targets **2014**, 562-566

126 Early-Stage Colorectal Cancer **2014**, 567-572

125 Recurrent and Metastatic Colorectal Cancer: Controversies, Consensus, and New Targets **2014**, 573-580

124 Hepatobiliary Cancer **2014**, 590-594

123 Neuroendocrine Tumors **2014**, 595-600

122 Transarterial Liver-Directed Therapies in Oncology **2014**, 601-605

121 Anal Cancer **2014**, 606-612

120 Renal Cancer: Tumor Diversity, Molecular Taxonomy, and Prognostic Algorithms **2014**, 613-620

119 Medical Management of Renal Cancer **2014**, 621-627

118 Medical Management of Bladder Cancer **2014**, 628-633

117 Prostate Cancer: Screening, Surveillance, Prognostic Algorithms and Independent Pathologic Predictive Parameters **2014**, 634-637

116 Medical Management of Prostate Cancer **2014**, 638-644

115 HER2-positive, trastuzumab-resistant metastatic esophageal cancer presenting with brain metastasis after durable response to dual HER2 blockade: a case report. *Journal of Gastrointestinal Oncology*, **2014**, 5, E103-8 2.8 10

114	Current standards of care for chemotherapy of optimally cytoreduced advanced epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2013 , 131, 241-5	4.9	26
113	Ovarian cancer survival: steady improvement, despite rhetoric to the contrary. <i>Current Oncology Reports</i> , 2013 , 15, 433-5	6.3	1
112	Provider impact on survival outcomes in the management of malignant disease. <i>Current Oncology Reports</i> , 2013 , 15, 193-6	6.3	
111	Chemoradiation in the management of cervix cancer: current status and future directions. <i>Oncology</i> , 2013 , 84, 246-50	3.6	23
110	Management of cancer in the elderly: an essential need for more clinically relevant data. <i>Oncology</i> , 2013 , 85, 166-7	3.6	1
109	New developments in the anti-neoplastic drug management of ovarian cancer. <i>F1000prime Reports</i> , 2013 , 5, 48		1
108	Risk of cervical cancer after HPV vaccination. <i>Current Pharmaceutical Design</i> , 2013 , 19, 1488-9	3.3	
107	Lapatinib as a therapeutic option in brain metastases from HER2+ breast cancer. <i>Annals of Palliative Medicine</i> , 2013 , 2, 35-6	1.7	1
106	Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2012 , 124, 171; author reply 171-2	4.9	4
105	Abandoning "TAP" as treatment of metastatic endometrial cancer: a serious example of the consequences resulting from the failure to adequately define the question being addressed in a phase 3 trial. <i>Current Oncology Reports</i> , 2012 , 14, 480-2	6.3	
104	Precision medicine and the rapidly approaching future of cancer management. <i>American Journal of Managed Care</i> , 2012 , 18, SP207-8, cover	2.1	
103	Ovarian cancer in 2011: Mutations and non-inferiority analyses show a way forward. <i>Nature Reviews Clinical Oncology</i> , 2011 , 9, 69-70	19.4	2
102	Counterpoint: chemosensitivity assays for recurrent ovarian cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011 , 9, 121-4	7.3	8
101	Can weekly topotecan substitute for a multi-day regimen in the treatment of ovarian cancer? Sadly, 10 years later the answer remains unknown. <i>Gynecologic Oncology</i> , 2011 , 122, 213-4	4.9	3
100	Combination Cytotoxic and Antiangiogenic Therapy in the Management of Epithelial Ovarian Cancer. <i>Combination Products in Therapy</i> , 2011 , 1, 1		
99	Commentary: Implications of cancer managed as a "chronic illness". <i>Current Oncology Reports</i> , 2011 , 13, 90-1	6.3	6
98	Information overload in oncology practice and its potential negative impact on the delivery of optimal patient care. <i>Current Oncology Reports</i> , 2011 , 13, 249-51	6.3	7
97	Involvement of bone in epithelial ovarian cancer: case report of an uncommon late metastatic event. <i>Case Reports in Oncology</i> , 2011 , 4, 490-1	1	1

96	Pegylated liposomal doxorubicin: appraisal of its current role in the management of epithelial ovarian cancer. <i>Cancer Management and Research</i> , 2011 , 3, 219-25	3.6	9
95	Serious ethical dilemma of single-agent pegylated liposomal Doxorubicin employed as a control arm in ovarian cancer chemotherapy trials. <i>Journal of Clinical Oncology</i> , 2010 , 28, e319-20; author reply e321-2	2.2	7
94	Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. <i>Journal of Clinical Oncology</i> , 2010 , 28, 3570-6	2.2	290
93	Combination versus sequential cytotoxic chemotherapy in recurrent ovarian cancer: time for an evidence-based comparison. <i>Gynecologic Oncology</i> , 2010 , 118, 6-7	4.9	8
92	Bypassing phase 1 trials in the cancer drug development paradigm: generally unwise and potentially dangerous. <i>Cancer</i> , 2010 , 116, 5116-8	6.4	
91	Presentation of chemotherapy options for cervix cancer on cancer-related Internet sites. <i>Journal of Women's Health</i> , 2009 , 18, 827-9	3	3
90	Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m ²) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: follow-up of a Southwest Oncology Group and Gynecologic Oncology Group phase 3 trial. <i>Gynecologic Oncology</i> , 2009 , 114, 195-8	4.9	104
89	Response to: "Establishing evidence for change in ovarian cancer surgery - Proposing clinical trials of cytoreductive surgery and hyperthermic chemotherapy (HIPEC) in ovarian cancer peritoneal carcinomatosis (Chua TC, et al.)". <i>Gynecologic Oncology</i> , 2009 , 115, 168	4.9	
88	Antiangiogenic drugs in ovarian cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2009 , 10, 2269-77	4	10
87	The myth of measurable disease in ovarian cancer: revisited. <i>Cancer Investigation</i> , 2009 , 27, 11-2	2.1	
86	Ovarian cancer. <i>Lancet, The</i> , 2009 , 374, 1371-82	4.0	477
85	An update on the use of intraperitoneal chemotherapy in the management of ovarian cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2009 , 15, 105-9	2.2	11
84	Optimal management of recurrent ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2009 , 19 Suppl 2, S40-3	3.5	19
83	Update on the utility of prognostic biomarkers in ovarian cancer. <i>F1000 Medicine Reports</i> , 2009 , 1,		1
82	Pharmaceutical management of ovarian cancer : current status. <i>Drugs</i> , 2008 , 68, 771-89	12.1	83
81	Antineoplastic agents in the management of ovarian cancer: current status and emerging therapeutic strategies. <i>Trends in Pharmacological Sciences</i> , 2008 , 29, 515-9	13.2	45
80	An Example of Ovarian Cancer as a Chronic Disease Process: 11-Year Survival with Multiple Treatments for Recurrent and Progressive Disease. <i>Case Reports in Oncology</i> , 2008 , 1, 1-4	1	2
79	Taxanes in the management of gynecologic malignancies. <i>Expert Review of Anticancer Therapy</i> , 2008 , 8, 219-26	3.5	5

78	Informing prospective research subjects of the influence of regulatory requirements for drug approval on the design of clinical trials in oncology. <i>Cancer</i> , 2007 , 109, 1003-6	6.4	1
77	The dangers of "cross-trial" and "cross-retrospective experience" comparisons: examples employing data in the peer-reviewed ovarian cancer literature. <i>Cancer</i> , 2007 , 109, 1929-32	6.4	7
76	An early signal of CA-125 progression for ovarian cancer patients receiving maintenance treatment after complete clinical response to primary therapy. <i>Journal of Clinical Oncology</i> , 2007 , 25, 3615-20	2.2	39
75	The CA125 antigen level as a prognostic versus a predictive test in epithelial ovarian cancer. <i>Nature Clinical Practice Oncology</i> , 2007 , 4, 628-9		3
74	New, expanded, and modified use of approved antineoplastic agents in ovarian cancer. <i>Oncologist</i> , 2007 , 12, 186-90	5.7	21
73	Concept of optimal surgical cytoreduction in advanced ovarian cancer: a brief critique and a call for action. <i>Journal of Clinical Oncology</i> , 2007 , 25, 4168-70	2.2	34
72	Intraperitoneal chemotherapy as primary treatment of advanced ovarian cancer: efficacy, toxicity, and future directions. <i>Reviews on Recent Clinical Trials</i> , 2007 , 2, 169-73	1.2	9
71	Justification for separate consideration of two broad categories of cancer patient use of complementary medicine. <i>Society for Integrative Oncology</i> , 2007 , 5, 50-2		
70	Randomized trial of adjuvant intraperitoneal alpha-interferon in stage III ovarian cancer patients who have no evidence of disease after primary surgery and chemotherapy: An intergroup study. <i>Gynecologic Oncology</i> , 2006 , 100, 133-8	4.9	51
69	Phase II trial of weekly paclitaxel (80 mg/m ²) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2006 , 101, 436-40	4.9	176
68	Intraperitoneal chemotherapy of ovarian cancer: a review, with a focus on practical aspects of treatment. <i>Journal of Clinical Oncology</i> , 2006 , 24, 988-94	2.2	151
67	The role of intraperitoneal chemotherapy in ovarian cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2006 , 4, 809-10	0.6	
66	Prolonged Disease-Free and Treatment-Free Survival in Platinum-Resistant Ovarian Cancer Following Extended (> 1 Year) Administration of Single-Agent Paclitaxel: A Case Report and Discussion of Potential Clinical Implications. <i>Cancer Investigation</i> , 2005 , 23, 33-35	2.1	3
65	A rationale for neoadjuvant systemic treatment followed by surgical assessment and intraperitoneal chemotherapy in patients presenting with non-surgically resectable ovarian or primary peritoneal cancers. <i>Journal of Cancer Research and Clinical Oncology</i> , 2005 , 131, 26-30	4.9	11
64	Prolonged disease-free and treatment-free survival in platinum-resistant ovarian cancer following extended (>1 year) administration of single-agent paclitaxel: A case report and discussion of potential clinical implications. <i>Cancer Investigation</i> , 2005 , 23, 33-5	2.1	
63	Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design. <i>Journal of Clinical Oncology</i> , 2004 , 22, 3120-5	2.2	185
62	Phase 2 trial of interferon-beta as second-line treatment of ovarian cancer, fallopian tube cancer, or primary carcinoma of the peritoneum. <i>Oncology</i> , 2004 , 66, 343-6	3.6	13
61	Ethical conflict in providing informed consent for clinical trials: a problematic example from the gynecologic cancer research community. <i>Oncologist</i> , 2004 , 9, 3-7	5.7	309

60	Can we do a better job preventing clinically-relevant peripheral neuropathy resulting from carboplatin/paclitaxel chemotherapy?. <i>Cancer Investigation</i> , 2004 , 22, 471-3	2.1	4
59	Activity of weekly paclitaxel in patients with advanced endometrial cancer previously treated with both a platinum agent and paclitaxel. <i>Gynecologic Oncology</i> , 2004 , 92, 180-2	4.9	10
58	Use of tamoxifen in asymptomatic patients with recurrent small-volume ovarian cancer. <i>Gynecologic Oncology</i> , 2004 , 93, 390-3	4.9	31
57	Examples of the marked variability in the relationship between the serum CA-125 antigen level and cancer-related symptoms in ovarian cancer. <i>Gynecologic Oncology</i> , 2004 , 93, 715-7	4.9	5
56	Survival following the documentation of platinum and taxane resistance in ovarian cancer: a single institution experience involving multiple phase 2 clinical trials. <i>Gynecologic Oncology</i> , 2004 , 93, 699-701	4.9	49
55	Phase 2 trial of carboplatin plus tamoxifen in platinum-resistant ovarian cancer and primary carcinoma of the peritoneum. <i>Gynecologic Oncology</i> , 2004 , 94, 404-8	4.9	17
54	Phase 2 trial of prolonged administration of oral topotecan in platinum/taxane-refractory ovarian, fallopian tube, and primary peritoneal cancers. <i>Gynecologic Oncology</i> , 2004 , 95, 109-13	4.9	7
53	Initial experience with a novel desensitization strategy for carboplatin-associated hypersensitivity reactions: carboplatin-hypersensitivity reactions. <i>Journal of Cancer Research and Clinical Oncology</i> , 2004 , 130, 25-8	4.9	39
52	Genetic discrimination arising from cancer risk assessments: a societal dilemma. <i>Cleveland Clinic Journal of Medicine</i> , 2004 , 71, 12, 15-8	2.8	
51	Second-line chemotherapy of epithelial ovarian cancer. <i>Expert Review of Anticancer Therapy</i> , 2003 , 3, 31-6	3.5	2
50	Managing taxane toxicities. <i>Supportive Care in Cancer</i> , 2003 , 11, 144-7	3.9	103
49	Consolidation/maintenance chemotherapy for ovarian cancer. <i>Current Oncology Reports</i> , 2003 , 5, 454-8	6.3	5
48	Limitations to the use of the CA-125 antigen level in ovarian cancer. <i>Current Oncology Reports</i> , 2003 , 5, 263-4	6.3	9
47	Phase 2 trial of single agent docetaxel in platinum and paclitaxel-refractory ovarian cancer, fallopian tube cancer, and primary carcinoma of the peritoneum. <i>Gynecologic Oncology</i> , 2003 , 91, 573-6	4.9	31
46	Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer. <i>Gynecologic Oncology</i> , 2003 , 90, 593-6	4.9	97
45	Carboplatin plus paclitaxel combination chemotherapy: impact of sequence of drug administration on treatment-induced neutropenia. <i>Gynecologic Oncology</i> , 2003 , 91, 118-22	4.9	7
44	Potential conflict between fundamental ethical principles and requirements of the oncology drug approval process: ethical conflict in drug approval. <i>Cancer</i> , 2003 , 98, 215-8	6.4	3
43	Informing patients with cancer of "new findings" that may influence their willingness to participate in research studies. <i>Cancer</i> , 2003 , 98, 885-7	6.4	7

42	Optimizing primary chemotherapy in ovarian cancer. <i>Hematology/Oncology Clinics of North America</i> , 2003 , 17, 957-68, viii	3.1	24
41	Intraperitoneal antineoplastic drug delivery: rationale and results. <i>Lancet Oncology, The</i> , 2003 , 4, 277-83	2.7	183
40	Toxicities of the platinum antineoplastic agents. <i>Expert Opinion on Drug Safety</i> , 2003 , 2, 597-607	4.1	110
39	Role of intraperitoneal chemotherapy in the front-line setting. <i>Journal of Clinical Oncology</i> , 2003 , 21, 145s-148s	2.2	10
38	Management of toxicities associated with the administration of taxanes. <i>Expert Opinion on Drug Safety</i> , 2003 , 2, 141-6	4.1	49
37	Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. <i>Journal of Clinical Oncology</i> , 2003 , 21, 2140-5	2.2	386
36	Expanded experience with an intradermal skin test to predict for the presence or absence of carboplatin hypersensitivity. <i>Journal of Clinical Oncology</i> , 2003 , 21, 4611-4	2.2	121
35	The needs of science vs the needs of patients: ethical concerns in cancer clinical trials. <i>Cleveland Clinic Journal of Medicine</i> , 2003 , 70, 1008-9, 1013-4, 1016	2.8	5
34	Are we winning or losing the war on cancer?. <i>Cleveland Clinic Journal of Medicine</i> , 2003 , 70, 632-3	2.8	1
33	Supportive care. <i>Cancer Chemotherapy and Biological Response Modifiers</i> , 2003 , 21, 709-16		
32	Rationale for maintenance or consolidation therapy in ovarian cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2003 , 1, 176-8	0.6	4
31	Second-line therapy of ovarian cancer with Paclitaxel administered by both the intravenous and intraperitoneal routes: rationale and case reports. <i>Gynecologic Oncology</i> , 2002 , 86, 95-8	4.9	5
30	Assessing cancer clinical trials: will your patient benefit from a Breakthrough?. <i>Cleveland Clinic Journal of Medicine</i> , 2002 , 69, 368-9, 375-6	2.8	1
29	Safety issues in using complementary and alternative medicine. <i>Journal of Clinical Oncology</i> , 2002 , 20, 39S-41S	2.2	45
28	Supportive care. <i>Cancer Chemotherapy and Biological Response Modifiers</i> , 2002 , 20, 627-32		
27	Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern	2.2	860
26	Neurotoxicity associated with a regimen of carboplatin (AUC 5-6) and paclitaxel (175 mg/m ² over 3 h) employed in the treatment of gynecologic malignancies. <i>Journal of Cancer Research and Clinical Oncology</i> , 2001 , 127, 55-8	4.9	30
25	Chronic administration of single-agent paclitaxel in gynecologic malignancies. <i>Gynecologic Oncology</i> , 2001 , 81, 201-5	4.9	17

24	Prevention and management of antineoplastic-induced hypersensitivity reactions. <i>Drug Safety</i> , 2001 , 24, 767-79	5.1	129
23	Intraperitoneal drug delivery of antineoplastics. <i>Drugs</i> , 2001 , 61, 1057-65	12.1	45
22	Cisplatin/Epinephrine Injectable Gel. <i>Drugs and Aging</i> , 2001 , 18, 794-795	4.7	
21	Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and fallopian tube and primary carcinoma of the peritoneum. <i>Journal of Clinical Oncology</i> , 2001 , 19, 1901-5	2.2	78
20	Paclitaxel-associated hypersensitivity reactions: experience of the gynecologic oncology program of the Cleveland Clinic Cancer Center. <i>Journal of Clinical Oncology</i> , 2000 , 18, 102-5	2.2	139
19	Phase II evaluation of 24-h continuous infusion topotecan in recurrent, potentially platinum-sensitive ovarian cancer: A Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2000 , 77, 112-5	4.9	34
18	Limits to the "benefits" from our oncologic interventions: a case report. <i>Gynecologic Oncology</i> , 2000 , 78, 261-2	4.9	3
17	Second-line treatment of ovarian cancer. <i>Oncologist</i> , 2000 , 5, 26-35	5.7	243
16	Clinical features of hypersensitivity reactions to carboplatin. <i>Journal of Clinical Oncology</i> , 1999 , 17, 1141-2	2.2	277
15	The use of paclitaxel and platinum-based chemotherapy in uterine papillary serous carcinoma. <i>Gynecologic Oncology</i> , 1999 , 74, 272-7	4.9	146
14	An effective and more convenient drug regimen for prophylaxis against paclitaxel-associated hypersensitivity reactions. <i>Journal of Cancer Research and Clinical Oncology</i> , 1999 , 125, 427-9	4.9	51
13	Serum CA-125 as a marker of disease activity in uterine papillary serous carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 1999 , 125, 697-8	4.9	26
12	Should Cost Be Considered in the Overall Evaluation of Phase II Clinical Trials of New Antineoplastic Therapies? A Response to the Essay from Dr. Eddie Reed. <i>Cancer Investigation</i> , 1998 , 16, 142-143	2.1	
11	Low-dose intravenous ondansetron (8 mg) plus dexamethasone: an effective regimen for the control of carboplatin-induced emesis. <i>Journal of Cancer Research and Clinical Oncology</i> , 1997 , 123, 224-6	4.9	8
10	The Role of CA-125 in the Management of Ovarian Cancer. <i>Oncologist</i> , 1997 , 2, 6-9	5.7	32
9	Low-dose intravenous ondansetron (8 mg) plus dexamethasone: an effective regimen for the control of carboplatin-induced emesis. <i>Journal of Cancer Research and Clinical Oncology</i> , 1997 , 123, 224-226	4.9	
8	Tumor chemosensitivity and chemoresistance assays. <i>Cancer</i> , 1996 , 77, 1020-5	6.4	33
7	Intraperitoneal chemotherapy in the treatment of ovarian cancer. <i>Annals of Medicine</i> , 1996 , 28, 293-6	1.5	10

6	Intraperitoneal Therapy of Ovarian Cancer. <i>Oncologist</i> , 1996 , 1, 18-21	5.7	11
5	Is there a role for intraperitoneal therapy in the management of gastrointestinal malignancies?. <i>Cancer Investigation</i> , 1995 , 13, 625-8	2.1	5
4	Second-line chemotherapy for refractory cancer: intraperitoneal chemotherapy. <i>Journal of Surgical Oncology</i> , 1994 , 10, 299-304		5
3	When regulatory requirements conflict with ethical study design: the case of oral ondansetron. <i>Cancer Investigation</i> , 1994 , 12, 654-6	2.1	18
2	Epithelial ovarian cancer in the elderly. The Memorial Sloan-Kettering Cancer Center experience. <i>Cancer</i> , 1993 , 71, 634-7	6.4	58
1	Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma. <i>Gynecologic Oncology</i> , 1992 , 45, 284-9	4.9	136